Genetically-engineered stem cells for self-regulating arthritis therapy

用于自我调节关节炎治疗的基因工程干细胞

基本信息

  • 批准号:
    10598619
  • 负责人:
  • 金额:
    $ 55.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2027-03-31
  • 项目状态:
    未结题

项目摘要

Abstract Arthritis-related conditions occur in over 1 in 5 adults, and the prevalence is increasing. Current approaches to modulate endogenous inflammatory mediators in rheumatoid arthritis (RA) predispose patients to significant adverse effects (AEs), such as infection, when anti-cytokine biologic drugs are delivered continually at fixed doses. As the severity of RA fluctuates over time, development of specific therapeutic strategies that can sense and respond to varying levels of endogenous inflammatory mediators by producing correspondingly appropriate levels of anti-cytokine drugs represents an attractive alternative approach that may mitigate AEs induced by continuous biologic administration. The goal of this project is to used genetically engineered stem cells to create bioartificial implants for biologic drug delivery as a therapy for RA. By combining principles of synthetic biology and tissue engineering, we will develop stem cells that respond to specific pro-inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor alpha by producing targeted anti-cytokine drugs in a feedback-controlled, self-regulating, and multiplexed manner. A primary focus of this study is to fine-tune these reprogrammed anti-inflammatory cells to enhance the sensitivity and specificity of cell-based drug delivery in response to low-level systemic inflammation. Synthetic gene circuits will also be introduced in these cells to allow for exogenously-controlled tunable and inducible safety switches that can temporarily or permanently disable anti-cytokine drug production. These engineered cells will be encapsulated in agarose-based implants that will be placed subcutaneously in mice induced with experimental RA, and the long-term safety and efficacy of these approaches will be assessed using clinical, histologic, molecular, and pain/behavior testing. The creation of such “designer” cells provides the possibility for long-term, feedback-controlled drug delivery for the treatment of chronic inflammatory diseases.
摘要 关节炎相关疾病发生在超过五分之一的成年人中,并且患病率正在增加。当前方法 调节类风湿性关节炎(RA)中的内源性炎症介质使患者易于 当输送抗细胞因子生物药物时,发生显著不良反应(AE),如感染 以固定剂量持续给药。由于RA的严重程度随时间而波动,因此开发特异性治疗药物可能是一个挑战。 这些策略可以通过产生不同水平的内源性炎症介质, 相应的适当水平的抗细胞因子药物代表了一种有吸引力的替代方法, 可减轻连续生物制剂给药引起的AE。这个项目的目标是利用基因 工程干细胞,以创造生物人工植入物的生物药物输送作为治疗RA。通过 结合合成生物学和组织工程学的原理,我们将开发出能够对 特异性促炎细胞因子如白细胞介素-1、白细胞介素-6和肿瘤坏死因子α, 以反馈控制、自我调节和多重方式产生靶向抗细胞因子药物。一 这项研究的主要焦点是微调这些重新编程的抗炎细胞,以增强免疫功能。 敏感性和特异性的细胞为基础的药物输送在低水平的全身炎症反应。合成 基因电路也将被引入这些细胞中,以允许外源控制的可调谐和可诱导的 可以暂时或永久禁用抗细胞因子药物生产的安全开关。这些工程化 将细胞包封在基于琼脂糖的植入物中, 实验性RA,这些方法的长期安全性和有效性将使用临床, 组织学、分子学和疼痛/行为测试。这种“设计者”细胞的创造提供了一种可能性, 用于治疗慢性炎症性疾病的长期反馈控制药物输送。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Farshid Guilak其他文献

Farshid Guilak的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Farshid Guilak', 18)}}的其他基金

Synthetic Chronogenetic Gene Circuits for Circadian Cell Therapies
用于昼夜节律细胞疗法的合成计时基因电路
  • 批准号:
    10797183
  • 财政年份:
    2023
  • 资助金额:
    $ 55.51万
  • 项目类别:
2023 Cartilage Biology and Pathology Gordon Research Conference and Gordon Research Seminar
2023年软骨生物学与病理学戈登研究会议暨戈登研究研讨会
  • 批准号:
    10605625
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:
Deconstructing Cartilage Mechanotransduction by Piezo Channels
通过压电通道解构软骨机械传导
  • 批准号:
    10533155
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:
SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage Repair
SMART 干细胞自主下调 TFG-β 信号传导以修复关节软骨
  • 批准号:
    10371823
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10707979
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10630757
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10434316
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:
SMART stem cells that autonomously down-modulate TFG-β signaling for Articular Cartilage Repair
SMART 干细胞自主下调 TFG-β 信号传导以修复关节软骨
  • 批准号:
    10590752
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:
Genetically-engineered stem cells for self-regulating arthritis therapy
用于自我调节关节炎治疗的基因工程干细胞
  • 批准号:
    10831324
  • 财政年份:
    2022
  • 资助金额:
    $ 55.51万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 55.51万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了